Find A Research Study


Study Title: A Study of INT-747 Monotherapy in Patients with Primary Biliary Cirrhosis
Category: Gastroenterology

Currently accepting participants?
Yes - please read the description below and contact the study coordinator if you are interested.

Principal Investigator: Kris Kowdley
Study Coordinator: Cheryl Saunders
Phone: 206-341-1786
Email: cheryl.saunders@vmmc.org

What is the A Study of INT-747 Monotherapy in Patients with Primary Biliary Cirrhosis study?

The study is a randomized, double-blind, placebo-controlled study and will involve taking one pill daily for 3 months.

Who can participate?

Men and women between the ages of 18 and 70 who have proven or likely PBC demonstrated by 2 of the 3 following criteria: 1) a history of increased alkaline phosphatase levels 2) a positive AMA titer 3) a liver biopsy consistent with PBC

Study Summary:

This study is designed to test the safety and effectiveness of a new medication to treat patients who have primary biliary cirrhosis.

Detailed Study Description:

(No information)

Study Design: Interventional, Blinded
Phase of Study: Phase II
Study Type: Interventional
Condition or Study Focus: primary biliary cirrhosis
Intervention Type: Drug
Intervention Name: INT-747
Gender: Male and Female
Age group: Interventional
Sponsor: Intercept Pharmaceuticals



Other studies in this category include:

Studies currently accepting study participants:

Studies currently not accepting study participants: